Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 6/20 | 0.52 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | KMO | O15229 | 1/20 | 0.48 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5666805 | 0.89 | KMO (0.62) | HTR2CHDAC4HDAC2HDAC8KMO | |
| SCHEMBL778529 | 0.88 | HDAC4 (0.63) | HTR2CHDAC4HDAC2HDAC8KMO | |
| SCHEMBL5667650 | 0.85 | KMO (0.64) | HTR2CHDAC4HDAC2HDAC8KMO | |
| SCHEMBL669730 | 0.85 | KMO (0.64) | HTR2CHDAC4HDAC2HDAC8KMO | |
| SCHEMBL24199719 | 0.84 | HTR2C (0.42) | HTR2CHDAC4HDAC2HDAC8KMO | |
| SCHEMBL1608042 | 0.84 | DRD2 (0.59) | HDAC4HDAC2HDAC8SIGMAR1DRD2 | |
| SCHEMBL1515269 | 0.84 | HTR2C (0.74) | HTR2CHDAC4NOTUMDRD2 | |
| SCHEMBL957833 | 0.84 | KDM1A (0.55) | HTR2CHDAC4HDAC2HDAC8KMO | |
| SCHEMBL1515236 | 0.84 | HTR2C (0.47) | HTR2CHDAC4HDAC2HDAC8 | |
| SCHEMBL19671564 | 0.84 | HTR2C (0.42) | HTR2CHDAC4HDAC2HDAC8KMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203055-A1 | FUSED RING COMPOUND AND APPLICATION THEREOF IN MEDICINE | BETTA PHARMACEUTICALS CO., LTD (CN) | 2023-06-29 | — | — | US | disclosed |
| EP-1101756-B1 | Aminopyrrolidine derivatives, processes for their preparation and pharmaceutical compositions comprising them | SERVIER LAB (FR) | 2003-03-19 | — | — | EP | disclosed |
| US-6300366-B1 | FOR THERAPY OF CARDIOVASCULAR DISEASES, ESPECIALLY ARTERIAL HYPERTENSION, ARRHYTHMIA | ADIR ET COMPAGNIE (FR) | 2001-10-09 | — | — | US | disclosed |
| EP-1101756-A1 | Aminopyrrolidine derivatives, processes for their preparation and pharmaceutical compositions comprising them | ADIR ET COMPAGNIE (FR) | 2001-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203055-A1 | FUSED RING COMPOUND AND APPLICATION THEREOF IN MEDICINE | VIP, CYP11B2, CYP11B1 | HTR2C 4362/4885HDAC4 787/4885HDAC2 1072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.